|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TRMT11 |
Gene summary for TRMT11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TRMT11 | Gene ID | 60487 |
| Gene name | tRNA methyltransferase 11 homolog | |
| Gene Alias | C6orf75 | |
| Cytomap | 6q22.32 | |
| Gene Type | protein-coding | GO ID | GO:0001510 | UniProtAcc | Q7Z4G4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 60487 | TRMT11 | CCI_2 | Human | Cervix | CC | 3.02e-03 | 5.96e-01 | 0.5249 |
| 60487 | TRMT11 | CCI_3 | Human | Cervix | CC | 1.12e-09 | 8.23e-01 | 0.516 |
| 60487 | TRMT11 | LZE7T | Human | Esophagus | ESCC | 4.50e-06 | 2.44e-01 | 0.0667 |
| 60487 | TRMT11 | LZE8T | Human | Esophagus | ESCC | 3.11e-06 | 1.05e-01 | 0.067 |
| 60487 | TRMT11 | LZE24T | Human | Esophagus | ESCC | 2.62e-14 | 1.99e-01 | 0.0596 |
| 60487 | TRMT11 | LZE6T | Human | Esophagus | ESCC | 3.12e-03 | 6.57e-02 | 0.0845 |
| 60487 | TRMT11 | P2T-E | Human | Esophagus | ESCC | 8.45e-10 | 2.11e-01 | 0.1177 |
| 60487 | TRMT11 | P4T-E | Human | Esophagus | ESCC | 2.00e-18 | 3.13e-01 | 0.1323 |
| 60487 | TRMT11 | P5T-E | Human | Esophagus | ESCC | 2.55e-14 | 1.70e-01 | 0.1327 |
| 60487 | TRMT11 | P8T-E | Human | Esophagus | ESCC | 6.27e-08 | 1.25e-01 | 0.0889 |
| 60487 | TRMT11 | P9T-E | Human | Esophagus | ESCC | 6.82e-08 | 5.51e-02 | 0.1131 |
| 60487 | TRMT11 | P10T-E | Human | Esophagus | ESCC | 1.84e-16 | 2.52e-01 | 0.116 |
| 60487 | TRMT11 | P11T-E | Human | Esophagus | ESCC | 5.71e-11 | 2.35e-01 | 0.1426 |
| 60487 | TRMT11 | P12T-E | Human | Esophagus | ESCC | 5.28e-17 | 3.28e-01 | 0.1122 |
| 60487 | TRMT11 | P15T-E | Human | Esophagus | ESCC | 6.58e-08 | 6.11e-02 | 0.1149 |
| 60487 | TRMT11 | P16T-E | Human | Esophagus | ESCC | 2.14e-17 | 3.13e-01 | 0.1153 |
| 60487 | TRMT11 | P17T-E | Human | Esophagus | ESCC | 1.77e-03 | 1.96e-01 | 0.1278 |
| 60487 | TRMT11 | P19T-E | Human | Esophagus | ESCC | 6.11e-06 | 2.72e-01 | 0.1662 |
| 60487 | TRMT11 | P20T-E | Human | Esophagus | ESCC | 2.54e-12 | 8.55e-02 | 0.1124 |
| 60487 | TRMT11 | P21T-E | Human | Esophagus | ESCC | 1.39e-11 | 3.80e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00226139 | Breast | Precancer | ribonucleoprotein complex biogenesis | 79/1080 | 463/18723 | 2.11e-18 | 1.03e-15 | 79 |
| GO:00422549 | Breast | Precancer | ribosome biogenesis | 52/1080 | 299/18723 | 7.35e-13 | 1.51e-10 | 52 |
| GO:00063646 | Breast | Precancer | rRNA processing | 35/1080 | 225/18723 | 7.90e-08 | 4.60e-06 | 35 |
| GO:00160726 | Breast | Precancer | rRNA metabolic process | 36/1080 | 236/18723 | 8.59e-08 | 4.84e-06 | 36 |
| GO:00344705 | Breast | Precancer | ncRNA processing | 42/1080 | 395/18723 | 9.91e-05 | 1.83e-03 | 42 |
| GO:00346604 | Breast | Precancer | ncRNA metabolic process | 45/1080 | 485/18723 | 1.15e-03 | 1.26e-02 | 45 |
| GO:002261314 | Breast | IDC | ribonucleoprotein complex biogenesis | 83/1434 | 463/18723 | 2.01e-13 | 5.20e-11 | 83 |
| GO:004225414 | Breast | IDC | ribosome biogenesis | 52/1434 | 299/18723 | 1.90e-08 | 1.32e-06 | 52 |
| GO:000636414 | Breast | IDC | rRNA processing | 35/1434 | 225/18723 | 4.59e-05 | 1.03e-03 | 35 |
| GO:001607214 | Breast | IDC | rRNA metabolic process | 36/1434 | 236/18723 | 5.48e-05 | 1.17e-03 | 36 |
| GO:002261324 | Breast | DCIS | ribonucleoprotein complex biogenesis | 83/1390 | 463/18723 | 3.65e-14 | 1.09e-11 | 83 |
| GO:004225423 | Breast | DCIS | ribosome biogenesis | 52/1390 | 299/18723 | 6.73e-09 | 5.44e-07 | 52 |
| GO:000636422 | Breast | DCIS | rRNA processing | 35/1390 | 225/18723 | 2.41e-05 | 5.62e-04 | 35 |
| GO:001607222 | Breast | DCIS | rRNA metabolic process | 36/1390 | 236/18723 | 2.86e-05 | 6.42e-04 | 36 |
| GO:003447011 | Breast | DCIS | ncRNA processing | 44/1390 | 395/18723 | 4.56e-03 | 3.49e-02 | 44 |
| GO:002261310 | Cervix | CC | ribonucleoprotein complex biogenesis | 88/2311 | 463/18723 | 2.11e-05 | 3.82e-04 | 88 |
| GO:004225410 | Cervix | CC | ribosome biogenesis | 62/2311 | 299/18723 | 2.48e-05 | 4.27e-04 | 62 |
| GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
| GO:00349685 | Cervix | CC | histone lysine methylation | 27/2311 | 115/18723 | 6.61e-04 | 6.09e-03 | 27 |
| GO:00165715 | Cervix | CC | histone methylation | 30/2311 | 141/18723 | 1.88e-03 | 1.39e-02 | 30 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TRMT11 | SNV | Missense_Mutation | c.317N>T | p.Ser106Phe | p.S106F | Q7Z4G4 | protein_coding | tolerated(0.07) | benign(0.153) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| TRMT11 | SNV | Missense_Mutation | rs759177203 | c.824G>A | p.Arg275His | p.R275H | Q7Z4G4 | protein_coding | tolerated(0.12) | probably_damaging(0.986) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TRMT11 | SNV | Missense_Mutation | rs144488568 | c.380G>A | p.Arg127Gln | p.R127Q | Q7Z4G4 | protein_coding | deleterious(0.02) | benign(0.322) | TCGA-ZX-AA5X-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| TRMT11 | SNV | Missense_Mutation | c.367G>A | p.Glu123Lys | p.E123K | Q7Z4G4 | protein_coding | tolerated(0.11) | benign(0.077) | TCGA-A6-2677-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Ancillary | leucovorin | SD | |
| TRMT11 | SNV | Missense_Mutation | c.429N>T | p.Lys143Asn | p.K143N | Q7Z4G4 | protein_coding | tolerated(0.18) | possibly_damaging(0.466) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| TRMT11 | SNV | Missense_Mutation | novel | c.333N>T | p.Lys111Asn | p.K111N | Q7Z4G4 | protein_coding | tolerated(0.61) | benign(0) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| TRMT11 | SNV | Missense_Mutation | c.167C>A | p.Ser56Tyr | p.S56Y | Q7Z4G4 | protein_coding | deleterious(0.04) | possibly_damaging(0.87) | TCGA-DC-5869-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| TRMT11 | SNV | Missense_Mutation | c.923N>T | p.Asp308Val | p.D308V | Q7Z4G4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TRMT11 | SNV | Missense_Mutation | novel | c.185N>C | p.Asn62Thr | p.N62T | Q7Z4G4 | protein_coding | tolerated(0.35) | benign(0.052) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TRMT11 | SNV | Missense_Mutation | novel | c.219A>G | p.Ile73Met | p.I73M | Q7Z4G4 | protein_coding | tolerated(0.16) | benign(0.097) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |